J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

John­son & John­son said that its com­bi­na­tion treat­ment staved off can­cer pro­gres­sion for longer than As­traZeneca’s block­buster Tagris­so as a first op­tion for pa­tients with a form of ad­vanced lung can­cer.

In the Phase III MARI­POSA study, J&J pit­ted its bis­pe­cif­ic an­ti­body Ry­bre­vant and ty­ro­sine ki­nase in­hibitor laz­er­tinib against Tagris­so alone. The study in­clud­ed 1,074 pa­tients with lo­cal­ly ad­vanced or metasta­t­ic EGFR-mu­tat­ed non-small cell lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.